Log in or Sign up for Free to view tailored content for your specialty!
Pharmacology News
Treat kids early, new migraine guideline says
The American Academy of Neurology and the American Headache Society clinical guideline for acute symptomatic treatment of migraines in children and teenagers — updated for the first time since 2004 — emphasizes importance of treating the migraine early and choosing the route of administration best suited to the characteristics of patient’s migraine attack
Pediatric migraine prevention guideline focuses on lifestyle choices
Pharmacologic treatments to prevent migraine in children and teens are effective, but so is placebo, complicating the issue for clinicians and families. Guidance from the American Academy of Neurology and the American Headache Society suggests that clinicians should counsel their patients on lifestyle and behavioral factors that contribute to migraine frequency, and it encourages shared decision-making with patients and caregivers regarding the use of preventive medication.
Log in or Sign up for Free to view tailored content for your specialty!
Should all pregnant women in the US be screened for hepatitis C?
In August, the U.S. Preventive Services Task Force issued a draft recommendation that encourages clinicians to screen all adults aged 18 to 79 years for HCV infection, including pregnant women. According to the USPSTF, HCV prevalence doubled among women aged 15 to 44 years between 2006 and 2014. Due to the increasing prevalence of the disease in this age group, the task force said clinicians “may want to consider screening pregnant persons aged younger than age 18 years.”
Should all pregnant women in the US be screened for hepatitis C?
In August, the U.S. Preventive Services Task Force issued a draft recommendation that encourages clinicians to screen all adults aged 18 to 79 years for HCV infection, including pregnant women. According to the USPSTF, HCV prevalence doubled among women aged 15 to 44 years between 2006 and 2014. Due to the increasing prevalence of the disease in this age group, the task force said clinicians “may want to consider screening pregnant persons aged younger than age 18 years.”
DAAs change treatment landscape for children with HCV
From 2013 through 2016, an estimated 2.4 million adults in the United States had a current hepatitis C virus infection. A study published in The American Journal of Public Health reported that the infection rate increased more than twofold between 2004 and 2014 as a result of the opioid epidemic.
DAAs change treatment landscape for children with HCV
From 2013 through 2016, an estimated 2.4 million adults in the United States had a current hepatitis C virus infection. A study published in The American Journal of Public Health reported that the infection rate increased more than twofold between 2004 and 2014 as a result of the opioid epidemic.
Rivaroxaban does not show noninferiority to vitamin K antagonists in antiphospholipid syndrome
Rivaroxaban failed to demonstrate noninferiority to dose-adjusted vitamin K antagonists in patients with thrombotic antiphospholipid syndrome, and the agent even showed a nonsignificant doubling of the risk for recurrent thrombosis, according to results from an open-label, randomized, noninferiority trial published in the Annals of Internal Medicine.
Statin intolerance can be fought with intermittent dosing
CHICAGO —Intermittent statin dosing is a treatment option that may have tremendous potential for addressing patients with statin intolerance who are trying to reduce LDL, according to a speaker at the Cardiometabolic Health Congress.
Icosapent ethyl appropriate to use to reduce CV risk, despite pending questions
CHICAGO — Findings of cardiovascular benefit with icosapent ethyl treatment from the REDUCE-IT trial have already revealed actionable clinical implications, but determining whether triglyceride reductions or eicosapentaenoic acid increases are the key mechanisms will be the focus of continuing research, according to a speaker at the Cardiometabolic Heath Congress.
Reyvow approved for acute migraine treatment
The FDA announced it approved Reyvow for the treatment of adults with acute migraine with or without aura.
-
Headline News
First US case of clade I mpox reported in California
November 18, 20242 min read -
Headline News
'On the frontlines of public health': Physicians leverage trust against firearm violence
November 19, 20246 min read -
Headline News
Data support early, continued lecanemab dosing for Alzheimer’s
November 19, 20242 min read
-
Headline News
First US case of clade I mpox reported in California
November 18, 20242 min read -
Headline News
'On the frontlines of public health': Physicians leverage trust against firearm violence
November 19, 20246 min read -
Headline News
Data support early, continued lecanemab dosing for Alzheimer’s
November 19, 20242 min read